Oppenheimer & CO Inc Myriad Genetics Inc Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 16,910 shares of MYGN stock, worth $181,444. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,910
Previous 18,066
6.4%
Holding current value
$181,444
Previous $494,000
53.24%
% of portfolio
0.0%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding MYGN
# of Institutions
228Shares Held
92MCall Options Held
297KPut Options Held
20.7K-
Black Rock Inc. New York, NY15.2MShares$163 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$114 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA6MShares$64.4 Million0.02% of portfolio
-
State Street Corp Boston, MA5.53MShares$59.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.35MShares$46.6 Million0.03% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $865M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...